TPX-0005

DRUG2 trials

Sponsors

Turning Point Therapeutics, Inc.

Conditions

Advanced Solid TumorKRAS Mutation-Related TumorsMetastatic Solid Tumor

Phase 1

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

TerminatedNCT05071183

Turning Point Therapeutics, Inc.Advanced Solid Tumor, KRAS Mutation-Related Tumors, Metastatic Solid Tumor

Start: 2021-09-23End: 2023-03-01Updated: 2024-04-02

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

WithdrawnNCT05828303

Turning Point Therapeutics, Inc.Advanced Solid Tumor, Metastatic Solid Tumor

Start: 2024-11-15End: 2025-11-30Updated: 2025-04-01